Erratum: Corrigendum to “Extended-release naltrexone opioid treatment at jail reentry (XOR)” (Contemporary Clinical Trials (2016) 51 (96) (S1551714416300593) (10.1016/j.cct.2016.05.002))

Ryan D. McDonald, Babak Tofighi, Eugene Laska, Keith Goldfeld, Wanda Bonilla, Mara Flannery, Nadina Santana-Correa, Christopher W. Johnson, Neil Leibowitz, John Rotrosen, Marc N. Gourevitch, Joshua D. Lee

Research output: Contribution to journalComment/debate

Abstract

We mistakenly stated that a modified Composite International Diagnostic Interview 2 (CIDI-2) will be used to assess opioid use disorder. Instead, we will use select items from the World Mental Health Composite International Diagnostic Interview [WMH-CIDI] (http://www.hcp.med.harvard.edu/wmhcidi/index.php) for that purpose. Page 59 under Section 2.4. Study population and inclusion/exclusion criteria should read “Eligible participants across all three arms are adults currently incarcerated in a New York City jail with a known release date, meet criteria for DSM-V current opioid use disorder based on a modified World Mental Health Composite International Diagnostic Interview (modified WMH-CIDI), an updated version of the CIDI-2 for Substance Use Disorders [21], and are of general good health.” In Table 2, “CIDI II DSM-5 checklist” should read “modified WMH-CIDI.” On page 62, the third paragraph under the Section 5.2 Secondary Outcomes should indicate use of the modified WMH-CIDI rather than the modified CIDI-2.

Original languageEnglish (US)
Number of pages1
JournalContemporary Clinical Trials
Volume51
DOIs
StatePublished - Nov 1 2016

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Erratum: Corrigendum to “Extended-release naltrexone opioid treatment at jail reentry (XOR)” (Contemporary Clinical Trials (2016) 51 (96) (S1551714416300593) (10.1016/j.cct.2016.05.002))'. Together they form a unique fingerprint.

  • Cite this